REGN logo

REGN Accounts receivable

Annual accounts receivable:

$6.21B+$544.60M(+9.61%)
December 31, 2024

Summary

  • As of today (May 27, 2025), REGN annual accounts receivable is $6.21 billion, with the most recent change of +$544.60 million (+9.61%) on December 31, 2024.
  • During the last 3 years, REGN annual accounts receivable has risen by +$175.40 million (+2.91%).
  • REGN annual accounts receivable is now at all-time high.

Performance

REGN Accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNbalance sheet metrics

Quarterly accounts receivable:

$5.56B-$650.90M(-10.48%)
March 31, 2025

Summary

  • As of today (May 27, 2025), REGN quarterly accounts receivable is $5.56 billion, with the most recent change of -$650.90 million (-10.48%) on March 31, 2025.
  • Over the past year, REGN quarterly accounts receivable has increased by +$338.80 million (+6.49%).
  • REGN quarterly accounts receivable is now -20.54% below its all-time high of $7.00 billion, reached on June 30, 2021.

Performance

REGN Quarterly accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNbalance sheet metrics

Accounts receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

REGN Accounts receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+9.6%+6.5%
3 y3 years+2.9%+14.9%
5 y5 years+163.2%+119.7%

REGN Accounts receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+16.6%-10.5%+14.9%
5 y5-yearat high+163.2%-20.5%+133.6%
alltimeall timeat high>+9999.0%-20.5%>+9999.0%

REGN Accounts receivable History

DateAnnualQuarterly
Mar 2025
-
$5.56B(-10.5%)
Dec 2024
$6.21B(+9.6%)
$6.21B(+1.7%)
Sep 2024
-
$6.11B(+6.8%)
Jun 2024
-
$5.72B(+9.5%)
Mar 2024
-
$5.22B(-7.9%)
Dec 2023
$5.67B(+6.4%)
$5.67B(+1.5%)
Sep 2023
-
$5.58B(+9.0%)
Jun 2023
-
$5.12B(+0.1%)
Mar 2023
-
$5.12B(-3.9%)
Dec 2022
$5.33B(-11.7%)
$5.33B(-4.0%)
Sep 2022
-
$5.55B(+7.5%)
Jun 2022
-
$5.16B(+6.7%)
Mar 2022
-
$4.84B(-19.8%)
Dec 2021
$6.04B(+46.7%)
$6.04B(+10.7%)
Sep 2021
-
$5.45B(-22.1%)
Jun 2021
-
$7.00B(+67.7%)
Mar 2021
-
$4.17B(+1.4%)
Dec 2020
$4.11B(+74.3%)
$4.11B(+15.8%)
Sep 2020
-
$3.55B(+49.3%)
Jun 2020
-
$2.38B(-6.0%)
Mar 2020
-
$2.53B(+7.2%)
Dec 2019
$2.36B(+5.2%)
$2.36B(-11.3%)
Sep 2019
-
$2.66B(+8.3%)
Jun 2019
-
$2.46B(+6.5%)
Mar 2019
-
$2.31B(+2.8%)
Dec 2018
$2.24B(+13.6%)
$2.24B(+1.8%)
Sep 2018
-
$2.20B(+8.0%)
Jun 2018
-
$2.04B(+4.9%)
Mar 2018
-
$1.94B(-1.5%)
Dec 2017
$1.97B(+22.5%)
$1.97B(+0.1%)
Sep 2017
-
$1.97B(+6.9%)
Jun 2017
-
$1.84B(+5.4%)
Mar 2017
-
$1.75B(+8.6%)
Dec 2016
$1.61B(+9.8%)
$1.61B(-2.0%)
Sep 2016
-
$1.64B(-6.2%)
Jun 2016
-
$1.75B(-6.1%)
Mar 2016
-
$1.87B(+27.1%)
Dec 2015
$1.47B(+50.3%)
$1.47B(+2.0%)
Sep 2015
-
$1.44B(+3.2%)
Jun 2015
-
$1.40B(+4.2%)
Mar 2015
-
$1.34B(+37.1%)
Dec 2014
$976.37M(+2.2%)
$976.37M(+5.3%)
Sep 2014
-
$927.25M(+3.7%)
Jun 2014
-
$893.92M(-14.7%)
Mar 2014
-
$1.05B(+9.7%)
Dec 2013
$954.97M(+37.8%)
$954.97M(-3.8%)
Sep 2013
-
$992.82M(+13.3%)
Jun 2013
-
$876.02M(+9.1%)
Mar 2013
-
$802.64M(+15.8%)
DateAnnualQuarterly
Dec 2012
$693.12M(+572.7%)
$693.12M(+36.8%)
Sep 2012
-
$506.68M(+44.9%)
Jun 2012
-
$349.64M(+119.3%)
Mar 2012
-
$159.46M(+54.8%)
Dec 2011
$103.03M(+25.8%)
$103.03M(+31.3%)
Sep 2011
-
$78.45M(-7.2%)
Jun 2011
-
$84.56M(-4.1%)
Mar 2011
-
$88.16M(+7.6%)
Dec 2010
$81.92M(+24.9%)
$81.92M(-0.4%)
Sep 2010
-
$82.29M(-13.6%)
Jun 2010
-
$95.20M(+32.5%)
Mar 2010
-
$71.86M(+9.6%)
Dec 2009
$65.57M(+86.2%)
$65.57M(-3.2%)
Sep 2009
-
$67.77M(+12.9%)
Jun 2009
-
$60.05M(+24.6%)
Mar 2009
-
$48.21M(+36.9%)
Dec 2008
$35.21M(+92.2%)
$35.21M(-16.6%)
Sep 2008
-
$42.21M(+28.5%)
Jun 2008
-
$32.84M(-0.4%)
Mar 2008
-
$32.96M(+79.9%)
Dec 2007
$18.32M(+144.5%)
$18.32M(+67.0%)
Sep 2007
-
$10.97M(-46.4%)
Jun 2007
-
$20.48M(-39.1%)
Mar 2007
-
$33.63M(+348.8%)
Dec 2006
$7.49M(-79.5%)
$7.49M(-5.6%)
Sep 2006
-
$7.94M(-34.6%)
Jun 2006
-
$12.14M(+10.3%)
Mar 2006
-
$11.01M(-69.9%)
Dec 2005
$36.52M(-15.3%)
$36.52M(+246.6%)
Sep 2005
-
$10.54M(-37.4%)
Jun 2005
-
$16.83M(+62.3%)
Mar 2005
-
$10.37M(-75.9%)
Dec 2004
$43.10M(+177.6%)
$43.10M(+73.3%)
Sep 2004
-
$24.87M(-2.1%)
Jun 2004
-
$25.40M(-57.6%)
Mar 2004
-
$59.88M(+285.6%)
Dec 2003
$15.53M(+286.6%)
$15.53M(+68.8%)
Sep 2003
-
$9.20M(+16.8%)
Jun 2003
-
$7.87M(+8.7%)
Mar 2003
-
$7.24M(+80.2%)
Dec 2002
$4.02M(+35.0%)
$4.02M(-11.1%)
Sep 2002
-
$4.52M(+51.4%)
Jun 2002
-
$2.99M(+9.0%)
Mar 2002
-
$2.74M(-7.9%)
Dec 2001
$2.98M(-78.5%)
$2.98M(-16.1%)
Sep 2001
-
$3.55M(-19.0%)
Jun 2001
-
$4.38M(-49.1%)
Mar 2001
-
$8.61M(-37.8%)
Dec 2000
$13.84M
$13.84M

FAQ

  • What is Regeneron Pharmaceuticals annual accounts receivable?
  • What is the all time high annual accounts receivable for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals annual accounts receivable year-on-year change?
  • What is Regeneron Pharmaceuticals quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals quarterly accounts receivable year-on-year change?

What is Regeneron Pharmaceuticals annual accounts receivable?

The current annual accounts receivable of REGN is $6.21B

What is the all time high annual accounts receivable for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high annual accounts receivable is $6.21B

What is Regeneron Pharmaceuticals annual accounts receivable year-on-year change?

Over the past year, REGN annual accounts receivable has changed by +$544.60M (+9.61%)

What is Regeneron Pharmaceuticals quarterly accounts receivable?

The current quarterly accounts receivable of REGN is $5.56B

What is the all time high quarterly accounts receivable for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high quarterly accounts receivable is $7.00B

What is Regeneron Pharmaceuticals quarterly accounts receivable year-on-year change?

Over the past year, REGN quarterly accounts receivable has changed by +$338.80M (+6.49%)
On this page